Summarized by Masters of Longevity from Longevity Technology.
An article previewing a lab study about a new oral compound that activates lysosomal cleanup pathways in aged mouse models of neurodegeneration, inviting readers to learn how researchers tested brain delivery and functional benefits across Alzheimer’s- and Parkinson’s-like models.
Key Takeaways
- LW-1017, an oral TRPML1 agonist, produced robust brain exposure and sustained autophagy marker changes in treated mice.
- In Parkinson’s models LW-1017 reduced alpha-synuclein, preserved dopaminergic neurons, and improved motor performance.
- In Alzheimer’s models LW-1017 reduced amyloid and tau pathology, lowered neuroinflammation, and improved cognition.
